Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Jan 8;33(1):30–35. doi: 10.1002/clc.20694

Clinical Implications of Thrombocytopenia Among Patients Undergoing Intra‐aortic Balloon Pump Counterpulsation in the Coronary Care Unit

Sion K Roy 1, Edward W Howard 1, Julio A Panza 2, Howard A Cooper 2,
PMCID: PMC6652948  PMID: 20063298

Abstract

Background

Thrombocytopenia Hypothesis: intra‐aortic balloon pump (IABP)‐associated thrombocytopenia is not associated with an increased risk of major bleeding or in‐hospital death. Thrombocytopenia is a common adverse effect of the IABP. However, the clinical implications of IABP‐associated thrombocytopenia are unknown.

Methods

We assessed the incidence and predictors of thrombocytopenia, and the association between thrombocytopenia and relevant clinical end points, using prospectively collected data on 252 consecutive patients undergoing IABP in a single coronary care unit (CCU).

Results

Anticoagulation with intravenous heparin was administered to 182 patients (72%). Baseline platelet counts were 232 000 ± 96 000 mL, decreased to 154 000 ± 74 000 mL at day 3, and recovered to baseline by day 8. Thrombocytopenia (nadir < 150 000 mL or > 50% reduction from baseline) occurred in 109 patients (43%), with a similar incidence among patients who received heparin and those who did not (45% vs 40%, P = 0.5). Independent predictors of thrombocytopenia were lower body weight, cardiogenic shock, and duration of IABP support. The incidence of both major bleeding and in‐hospital death were higher among patients who developed thrombocytopenia than among those who did not (13.8% vs 4.2%, P = 0.01 and 28% vs 16%, P = 0.02, respectively). However, after controlling for confounding variables, thrombocytopenia was not an independent predictor of either major bleeding (odds ratio [OR]: 2.2, 95% confidence interval [CI]: 0.8–6.4, P = 0.1) or in‐hospital death (OR: 1.5, 95% CI: 0.8–2.9, P = 0.3).

Conclusions

Among patients undergoing IABP in the CCU, thrombocytopenia is generally mild, appears to be unrelated to concomitant heparin use, and is not associated with an increased risk of major bleeding or in‐hospital death. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (646.5 KB).

References

  • 1. Bream‐Rouwenhorst HR, Hobbs RA, Horwitz PA. Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra‐aortic balloon pump counterpulsation. J Interv Cardiol 2008; 21(4): 350–356. [DOI] [PubMed] [Google Scholar]
  • 2. Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra‐aortic balloon pumps. Am J Med 1998; 105(1): 27–32. [DOI] [PubMed] [Google Scholar]
  • 3. McCabe JC, Abel RM, Subramanian VA, et al. Complications of intra‐aortic balloon insertion and counterpulsation. Circulation 1978; 57(4): 769–773. [DOI] [PubMed] [Google Scholar]
  • 4. Gore JM, Spencer FA, Gurfinkel EP, et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009; 103(2): 175–180. [DOI] [PubMed] [Google Scholar]
  • 5. Leinbach RC, Nyilas E, Caulfield JB, et al. Evaluation of hematologic effects of intra‐aortic balloon assistance in man. Trans Am Soc Artif Intern Organs 1972; 18(0): 493–500, 512. [DOI] [PubMed] [Google Scholar]
  • 6. Cooper HA, Thompson E, Panza JA. The role of heparin anticoagulation during intra‐aortic balloon counterpulsation in the coronary care unit. Acute Card Care 2008; 10(4): 214–220. [DOI] [PubMed] [Google Scholar]
  • 7. Moulopoulos SD, Topaz S, Kolff WJ. Diastolic balloon pumping (with carbon dioxide) in the aorta—a mechanical assistance to the failing circulation. Am Heart J 1962; 63: 669–675. [DOI] [PubMed] [Google Scholar]
  • 8. Kantrowitz A, Tjonneland S, Freed PS, et al. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA 1968; 203(2): 113–118. [PubMed] [Google Scholar]
  • 9. Bregman D, Nichols AB, Weiss MB, et al. Percutaneous intra‐aortic balloon insertion. Am J Cardiol 1980; 46(2): 261–264. [DOI] [PubMed] [Google Scholar]
  • 10. Laish‐Farkash A, Hod H, Matetzky S, et al. Safety of intra‐aortic balloon pump using glycoprotein IIb/IIIa antagonists. Clin Cardiol 2009; 32(2): 99–103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Trost JC, Hillis LD. Intra‐aortic balloon counterpulsation. Am J Cardiol 2006; 97(9): 1391–1398. [DOI] [PubMed] [Google Scholar]
  • 12. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin‐induced thrombocytopenia. Circulation 2005; 111(20): 2671–2683. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES